Skip to content

Effect and neural mechanism of cerebellar iTBS on balance and walking ability in patients with supratentorial stroke

Effect and neural mechanism of cerebellar iTBS on balance and walking ability in patients with supratentorial stroke

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300077916
Enrollment
Unknown
Registered
2023-11-23
Start date
2023-12-01
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Interventions

Control group (Experiment 3):sham iTBS
Healthy Intervention group (Experiment 1):single iTBS
Healthy control group (Experiment 1):single sham iTBS
Stroke group (Experiment 2):none
Healthy control group(Experiment 2):none
Intervention group (Experiment 3):cerebellum iTBS

Sponsors

Changzhou De'an Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Stroke patients: (1) Diagnosed as supratentorial stroke according to the Chinese classification of cerebrovascular disease 2015 and were confirmed by MRI or CT; (2) First, unilateral onset and stable disease; (3) Unilateral paralysis; (4) Aged 18-80 years old; (5) The course of the disease was between 1-12 months; (6) Conscious and cooperative, cognitive ability, MMSE >= 20; (7) Brunnstrom III-V stage, (8) Orthostatic balance >= 1 grade, (9) Informed consent signed by family members and patients. 2. Healthy Subjects: (1) Aged 18-80 years old; (2) Former healthy, no serious nervous and motor system disease; (3)Right-handed; (4) Signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Cerebral stem and cerebellar stroke; 2. Patients with progressive stroke or malignant progressive hypertension, serious visceral system diseases, malignant tumors, etc.; 3. Previous history of organic brain diseases, mental disorders, epilepsy; 4. Patients with metal implantation or skull defect in the skull; 5. Treatment of local skin damage, inflammation or hyperalgesia in irritated areas; 6. The improved Ashworth score of the affected lower extremity was greater than grade 2. 7. Participants with vestibular dysfunction, those who exhibit an unusually strong response to transcranial magnetic stimulation, those taking medications known to influence the effects of transcranial magnetic stimulation, as well as individuals who have participated in transcranial magnetic stimulation interventions in the recent past

Design outcomes

Secondary

MeasureTime frame
functional near infrared spectroscopy;Fugl-Meyer assessment sacle;

Primary

MeasureTime frame
Berg Balance scale;modified Barthel index;Mini-mental State Examination;gait speed ;

Countries

China

Contacts

Public ContactShizhe Zhu, Tong Wang

Nanjing Medical University/Changzhou De'an Hospital

wangtong60621@163.com+86 139 5168 0478

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026